Pongchaiyakul Chatlert, Driessen Stefan
Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Established Pharmaceuticals Division, Global Biometrics, Abbott Healthcare Products B.V, Weesp, Netherlands.
Front Digit Health. 2025 Jul 7;7:1502990. doi: 10.3389/fdgth.2025.1502990. eCollection 2025.
Dyslipidemia, a key modifiable risk factor for cardiovascular diseases, is managed using lipid-lowering therapies. Medication adherence for dyslipidemia treatment is poor across the globe, impacting treatment effectiveness. This highlights the need for scalable strategies, such as mobile app-based behavioral interventions, to enhance adherence to lipid-lowering therapies.
The study assesses the impact of "My A:Care" and "My A:Care Smart Coach" mobile interventions on adherence to dyslipidemia treatment.
This proof-of-concept, open-label, single-center study randomized 150 patients with suboptimal adherence to dyslipidemia treatment into three groups (1:1:1): My A:Care, My A:Care Smart Coach (intervention), and a no-app control group. Participants were monitored over 12 weeks. The primary objective was to assess changes in medication adherence, with secondary outcomes including changes in lipid parameters and beliefs about lipid-lowering medications. The study also explored the association between adherence and app engagement.
At week 12, the Medication Adherence Report with Visual Analog Scale (MARS-5VA) Part 1 scores were modestly, but significantly lower in the control group compared to the intervention groups: Mean (SD); No-App: -0.3 (0.9), Smart Coach: 0.0 (0.7) [ = 0.035], My A:Care-All: 0.0 (0.7) [ = 0.056]. Compared to the control, the intervention groups also showed greater improvements in non-HDL-C levels [% change (SE): My A:Care-All: -5.5% (3.2), Smart Coach: -4.3% (3.7), No-App: -1.8% (3.7)], along with favorable trends in TC, LDL-C, and HDL-C.
This proof-of-concept study suggests that the My A:Care and Smart Coach apps may positively impact adherence to lipid-lowering therapy in patients with dyslipidemia. The positive adherence outcomes and potential benefits in lipid control indicate promising early signals that warrant further investigation in larger, confirmatory studies.
NCT05370703.
血脂异常是心血管疾病的一个关键可改变风险因素，可通过降脂治疗进行管理。全球范围内血脂异常治疗的药物依从性较差，影响了治疗效果。这凸显了需要可扩展的策略，如基于移动应用的行为干预措施，以提高降脂治疗的依从性。
本研究评估“My A:Care”和“My A:Care Smart Coach”移动干预措施对血脂异常治疗依从性的影响。
这项概念验证、开放标签、单中心研究将150例血脂异常治疗依从性欠佳的患者随机分为三组（1:1:1）：My A:Care组、My A:Care Smart Coach组（干预组）和无应用程序对照组。对参与者进行了12周的监测。主要目标是评估药物依从性的变化，次要结局包括血脂参数的变化以及对降脂药物的认知。该研究还探讨了依从性与应用程序参与度之间的关联。
在第12周时，与干预组相比，对照组的视觉模拟量表药物依从性报告（MARS - 5VA）第1部分得分虽有小幅但显著降低：均值（标准差）；无应用程序组：-0.3（0.9），Smart Coach组：0.0（0.7）[P = 0.035]，My A:Care - 全部组：0.0（0.7）[P = 0.056]。与对照组相比，干预组的非高密度脂蛋白胆固醇（non - HDL - C）水平也有更大改善[变化百分比（标准误）：My A:Care - 全部组：-5.5%（3.2），Smart Coach组：-4.3%（3.7），无应用程序组：-1.8%（3.7）]，总胆固醇（TC）、低密度脂蛋白胆固醇（LDL - C）和高密度脂蛋白胆固醇（HDL - C）也呈现出有利趋势。
这项概念验证研究表明，My A:Care和Smart Coach应用程序可能对血脂异常患者的降脂治疗依从性产生积极影响。积极的依从性结果以及在血脂控制方面的潜在益处表明了有前景的早期信号，值得在更大规模的验证性研究中进一步调查。
NCT05370703。
